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Abstract: Miliary pattern of pulmonary metastases is a rarity in
patients with lung cancer. We report five cases of patients with a
never-smoking adenocarcinoma of the lung with such a pattern of
metastases. In the tumor cells of all five patients, epidermal growth
factor receptor (EGFR) mutation gene sequencing identified a dele-
tion in exon 19 of the EGFR gene, and all five patients had a
dramatic response to EGFR tyrosine kinase inhibitors. No echino-
derm microtubule-associated protein-like 4 (EML4)-anaplastic lym-
phoma kinase (ALK) translocation was detected. We believe that the
miliary never-soking adenocarcinoma of the lung is a distinct
clinically relevant subgroup of the never-smoking non-small cell
lung cancer. Physician should recognize this subgroup of patients
with lung cancer when facing a picture of miliary pulmonary
metastases in chest x-ray or computed tomography scan in patients
with a history of never smoking and consider upfront therapy with
EGFR tyrosine kinase inhibitors.
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Miliary pattern of pulmonary metastases is a rarity inpatients with lung cancer. Five of our patients with lung
cancer had a never-smoking adenocarcinoma with such a
pattern of metastases.
CASE 1
A woman from Thailand, aged 40 years, was diagnosed
in 2007 with a moderately differentiated acinar adenocarci-
noma of the lower lobe of the right lung and miliary pulmo-
nary metastases in both lungs (100 metastases per side) and
a brain metastasis. A deletion in exon 19 of the epidermal
growth factor receptor (EGFR) gene (p.E746_A750del) was
detected in the tumor cells of the brain metastasis (Figure 1).
Patient was treated with the EGFR-tyrosine kinase inhibitor
(EGFR-TKI) erlotinib as first-line therapy. Seven weeks later,
computed tomography (CT) scan demonstrated a complete
remission of the primary tumor and of the miliary lung
metastases (Figures 2A, B). Patient was 19 months in com-
plete remission before the tumor progressed.
CASE 2
A woman from Germany, aged 70 years, was diag-
nosed in 2008 with a moderately differentiated acinar
adenocarcinoma of the upper lobe of the right lung, with
involved ipsilateral and contralateral lymph nodes of the
mediastinum, malignant pleural effusion, and miliary pul-
monary metastases in both lungs. Tumor progression was
observed after two cycles of first-line chemotherapy car-
boplatin and etoposide. EGFR mutations gene sequencing
identified a deletion in exon 19 of the EGFR gene (Figure
1). Therefore, we started second-line therapy with erlo-
tinib. One month later, chest x-ray showed an extremely
rapid response of the miliary lung metastasis and a partial
remission of the primary tumor and the malignant pleural
effusion (Figure 3), which was confirmed by CT scan
(Figures 2C, D). Most of the miliary pulmonary metastases
were no longer detectable. Patient was 19 months in partial
remission before the tumor progressed.
CASE 3
A young woman from Germany, aged 42 years, was
diagnosed in 2008 with a moderately differentiated acinar ade-
nocarcinoma of the lung, which was localized in the upper lobe
of the right lung. At the time of diagnosis, she had extensive
disease with metastases in liver, bone, mediastinal lymph nodes,
and a malignant pericardial effusion and the picture of miliary
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pulmonary metastases. The patient was treated with first-line
chemotherapy containing carboplatin and paclitaxel. After three
cycles of chemotherapy, the CT scan demonstrated progressive
disease. Erlotinib was started as second-line therapy. Four
months later, the CT scan revealed a partial remission of all
tumor lesions, and the miliary lung metastases had almost
disappeared (Figures 2E, F). Patient was 8 months in partial
remission before the tumor progressed in the liver, whereas the
lung metastases were still in remission. Also, in this patient, a
deletion in exon 19 of the EGFR gene (p.E746_A750del) was
detected in the tumor cells (Figure 1).
CASE 4
A man from Germany, aged 63 years, was dia-
gnosed in 2004 with a moderately differentiated acinar
adenocarcinoma of the lung, which was localized in the
lower lobe of the right lung. At the time of diagnosis, he
had involved mediastinal lymph nodes and miliary
pulmonary metastases in both lungs. Patient was treated
with two cycles of cisplatin and gemcitabine as first-line
chemotherapy and with three cycles of pemetrexed as
second-line chemotherapy, whereby the patient had pro-
gressive disease after both therapies. Erlotinib was started
as third-line treatment. Two, 4, 6, and 8 months later,
the CT scan revealed a dramatic response of all tumor
lesions. Altogether, the patient was 12 months in re-
mission before tumor progressed. The latest performed
EGFR mutation analysis also detected a deletion in exon
19 of the EGFR gene (p.E746_A750del) in the tumor cells
(Figure 1).
FIGURE 1. Epidermal growth factor receptor (EGFR) sequence analysis results of exon 19. A and B, EGFR wild-type sequence
by forward and reverse sequencing. C–E, Sequence analysis results of cases 1, 2, 3, 4, and 5 by forward (C, D, and G) or re-
verse (E and F) sequencing. Case 1: c.2238_2252del; case 2: c.2237GA and c.2238_2252del; case 3: c.2238_2252del; case
4: c.2238_2252del; and case 5: c.2238_2252del (an arrow point out the mutation for each case).
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CASE 5
A man from Germany, aged 68 years, was diagnosed in
2008 with a moderately differentiated acinar adenocarcinoma
of the upper lobe of the left lung, with involved lymph nodes
of the mediastinum, malignant pleural effusions, bone metas-
tases, one liver metastasis, and miliary pulmonary metastases
in both lungs. We analyzed tumor tissue for harboring EGFR
gene mutations. EGFR mutations gene sequencing also iden-
tified a deletion in exon 19 of the EGFR gene (Figure 1).
Therefore, we started first-line therapy with erlotinib per day.
CT scans showed an extremely rapid response of the miliary
lung metastasis and the primary tumor and a complete remis-
sion of the liver metastasis, the malignant pleural effusions,
and the involved lymph nodes. Patient was 18 months in
complete remission before the tumor progressed.
All five patients presented in this study were lifelong
never smokers, had the radiologic picture of miliary pulmo-
nary metastases, and in all five cases, the pathologic assess-
ment of tumor biopsies showed acinar adenocarcinoma of the
lung. Neither of them had histologic or radiologic features of
bronchioloalveolar carcinoma.1 In the tumor cells of all five
patients, EGFR mutation gene sequencing identified a dele-
tion in exon 19 of the EGFR gene, thus all five patients had
a dramatic response to EGFR TKIs.2 In cases 1 and 5,
erlotinib was given as first-line treatment, in cases 2 and 3 as
second-line treatment, and in case 4 as third-line treatment.
Further, to identify ALK rearrangements, fluorescence
in situ hybridization analysis was performed in the tumor
cells of all five patients. However, no EML4-ALK transloca-
tion was detected.
DISCUSSION
Lung cancer can metastasize in each organ and region
of the body, but typically, lung cancer spreads into locore-
gional lymph nodes and favors liver, bone, brain, and adrenal
glands as sites of distant metastases. Sometimes, few pulmo-
nary metastases or satellite tumors in the lung are observed.
A miliary pattern of lung metastases, which is characterized
by hundreds of small metastases scattered throughout the
entire lung, is a rarity in patients with lung cancer. We had
never observed this pattern of metastases in our patients with
lung cancer with a history of smoking nor has this miliary
pattern of lung metastases in current, recent, or former smok-
ers been reported in the literature.
Our patient cohort shows striking similarities to five
patients with adenocarcinomas of the lung with miliary me-
tastases to the lung reported in 1993 by Umeki.3 Umeki
identified five cases in a consecutive cohort of 630 patients,
suggesting that the prevalence of miliary phenotype may
approximately 1% in Japanese patients.3 The author reported
a short survival time after appearance of the miliary lung
FIGURE 2. Transverse computed tomography (CT) images
(window center/window width: 450/1800 Houndsfield units)
represents the three patients before treatment (A: case 1, C:
case 2, and E: case 3) and horizontally corresponding im-
ages of the same patients (B: 7 weeks later, D: 8 weeks later,
and F: 17 weeks later) after treatment with EGFR tyrosine
kinase inhibitor erlotinib. The right column of images dem-
onstrates a clearly visible reduction of metastasis in size and
number.
FIGURE 3. Case 2: conventional chest x-rays
prior (A) and 4 weeks posttreatment with epider-
mal growth factor receptor (EGFR) tyrosine kinase
inhibitor erlotinib (B) illustrate not only a fulmi-
nant decrease of the miliary lung metastases but
also a reduction of size of the primary tumor side
of the right upper lobe (arrows) and of the pleural
effusion.
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metastases and suggested that the unique pattern of multiple
pulmonary metastases was secondary to bone metastases,
because all his five patients also had had bone metastases.3 In
contrast, three of our five patients with a miliary never-
smoking adenocarcinoma of the lung had no bone metastases.
A specific molecular phenotype facilitating tumor cell hom-
ing to the lungs may represent an alternative explanation to
the unique metastatic traits of the miliary never-smoking
adenocarcinoma of the lung. Our finding of identical exon 19
deletions (p.E746_A750del) and of negative EML4-ALK re-
arrangements in the tumors of all five patients argues for a
common molecular signature of these tumors. Additionally to
our five patients, Sebastian et al.4 reported the case of a
37-year-old man from Germany, who had never smoked and
had also such a miliary pulmonary metastases of an adeno-
carcinoma of the lung. In this study, we report the miliary
never-smoking adenocarcinoma of the lung as one distinct
subtype of never-smoking non-small cell lung cancer char-
acterized by a unique (miliary) pattern of lung metastases in
combination with a specific histologic (adenocarcinoma) and
genetic (EGFR exon 19 deletions and no EML4-ALK rear-
rangements) phenotype.
The miliary never-smoking adenocarcinoma of the lung
occurred in women and in men and in whites and in Asians.
Although being rare, this finding has high clinical relevance,
and physicians should be aware of this entity and the need for
early treatment with EGFR TKIs after detection of activating
EGFR gene mutations.
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